## Verdict

verdict: PASS

```json
{"phase":"7.5","verdict":"PASS","iterations":1,"compound_risk_tier":"experimental","compound_entry_path":"vault/compounds/ss-31.md","required_fields":{"adverse_effects_literature":"populated","contraindications":"populated","monitoring":"populated","stopping_criteria":"populated"},"third_party_monitoring_marker_present":true,"third_party_markers":["injection-site reaction assessment at each visit","eosinophil count (periodic, ≥30-day intervals)","knee extensor muscle strength (median +63 N at 168 weeks; 6MWT used in TAZPOWER OLE and MMPOWER-3)","eGFR at baseline and periodically"],"halt_reasons":[]}
```

---

## Verification Detail

### Source files reviewed
- `/Users/waltermcgivney/Documents/Projects/aplus-wiki-research/vault/library/peptides/ss-31/research-report.md` (§4.4, §4.5)
- `/tmp/aplus-research/ss-31/sections/section-D.md` (§D.4, §D.5)

Both files are consistent and mutually corroborating on every risk-floor field below.

---

### Field 1: adverse_effects_literature — POPULATED

The AE profile is well-characterized across three independent programs (TAZPOWER, MMPOWER-3, ReCLAIM-2), each with controlled or large-cohort data.

**TAZPOWER (n=12 controlled, 40 mg SC QD):**
> "Any ISR: elamipretide 100%, placebo 67%; Erythema: 100% vs 25%; Pain: 75% vs 33%; Induration: 67% vs 17%; Pruritus: 67% vs 17%. No serious drug-related adverse events in the controlled phase; 2 discontinuations due to ISRs in the 168-week OLE."

**MMPOWER-3 (n=218, 40 mg SC × 24 weeks):**
> "Treatment-emergent AEs predominantly mild-to-moderate; most common = ISRs (erythema, pain, induration, pruritus, bruising); no cardiovascular safety signal; severe ISRs requiring dose modification <5%."

**ReCLAIM-2 (n=117 elamipretide, 48 weeks):**
> "Eosinophil count increased: 6.0% vs 0%; SAEs treatment-related: 0% vs 0%; Discontinuation due to AEs: 8.5% (protocol-coded) / 24.8% (clinical narrative)."

**Eosinophilia characterization (from prescribing information [1]):**
> "Transient eosinophil count elevations were observed in studies ≥30 days; mean peak increase 0.5–0.6 × 10³/µL at ~90 days, resolving within 6–12 months."

**Systemic safety:**
> "No cardiovascular safety signal identified above placebo rates in any cardiac trial program."

**Verdict on field:** Injection-site reactions as the dominant class, transient eosinophilia as the only notable hematologic signal, and no treatment-related SAEs — all quantified from controlled and Phase 3 data. Fully populated.

---

### Field 2: contraindications — POPULATED

From the Forzinity prescribing information (NDA 215244, DailyMed) as cited in both source files:

> "**Contraindications [1]:** Serious hypersensitivity to elamipretide or any Forzinity excipient."

> "**Warnings and precautions [1]:**
> 1. Hypersensitivity reactions: Including serious allergic responses with rash, papular lesions, and respiratory symptoms. May occur within minutes to months after initiation. Monitor for signs.
> 2. Benzyl alcohol toxicity: Forzinity contains 20 mg/mL benzyl alcohol as preservative; relevant consideration for compounded formulations without preservative-free designation."

The contraindication is non-empty, grounded in the FDA PI, and covers both the principal allergic and excipient-toxicity vectors. Fully populated.

---

### Field 3: monitoring — POPULATED

Both source files carry an explicit monitoring framework grounded in the Forzinity PI and trial safety data:

> "**Monitoring framework:**
> - Assess injection sites at each visit; document ISR severity and type
> - Monitor for hypersensitivity (rash, urticaria, respiratory symptoms) especially in first weeks
> - Periodic eosinophil count at ≥30-day intervals
> - eGFR at baseline and periodically; dose reduce if eGFR falls below 30 mL/min
> - No routine cardiac monitoring specified; cardiovascular safety well-characterized without signal"

Section D.5 replicates this with the eosinophilia note:
> "No specific eosinophilia stopping threshold is defined in the Forzinity prescribing information; clinical judgment guides management of persistent or severe elevations."

Named objective markers confirmed present: ISR site assessment, eosinophil count, eGFR. Fully populated.

---

### Field 4: stopping_criteria — POPULATED

Both source files carry explicit stopping criteria:

> "**Stopping criteria:**
> - Serious hypersensitivity reaction → discontinue immediately
> - Intolerable ISRs unresponsive to site rotation and local measures → consider discontinuation
> - Severe renal impairment development during treatment → dose reduce by 50%, do not stop"

The "eosinophilia: no defined threshold in PI" honesty is also present:
> "No specific eosinophilia stopping threshold is defined in the Forzinity prescribing information; clinical judgment guides management of persistent or severe elevations."

This is the appropriate intellectually honest framing — the PI does not define a numeric eosinophil count as a stopping threshold, and the report states this explicitly rather than fabricating one. Fully populated.

---

### Third-party objective monitoring marker — PRESENT (×4 named markers)

The gate requires ≥1 named objective assay. The report contains four:

1. **Injection-site reaction assessment** — assessed at each clinical visit; grade recorded by type (erythema, induration, pruritus, pain, mass, swelling); sourced from PI and trial protocols.
2. **Eosinophil count** — named lab marker, periodic monitoring ≥30-day intervals, mean peak +0.5–0.6 × 10³/µL at ~90 days per PI [1].
3. **Knee extensor muscle strength / 6MWT** — the primary clinical endpoints in TAZPOWER OLE and MMPOWER-3; median +63 N at week 168 used as the FDA accelerated-approval endpoint; 6MWT quantified to ~43 m change per arm in TAZPOWER controlled phase. These are named functional assays used in the clinical trial monitoring program.
4. **eGFR** — renal function monitoring at baseline and periodically; dose-adjustment threshold at eGFR <30 mL/min.

The third-party_monitoring_marker_present field is TRUE with a rich marker set.

---

### Experimental risk tier — rationale

Forzinity's FDA approval is for a single ultra-rare monogenic disease (Barth syndrome, ≤200 US patients) under accelerated approval contingent on a confirmatory trial. Every controlled RCT across five indications missed its primary endpoint. Off-label / grey-market use carries no regulatory backing, no trial-derived dose-response relationship, and an unverified supply chain. Treating the compound_risk_tier as **experimental** for the wiki's off-label / performance frame is correct: the approval does not establish benefit in any broader population, the confirmatory trial is pending, and the grey-market sourcing vector is completely unvalidated.

---

### Summary

All four required risk-floor fields are populated from retrieved primary sources (Forzinity PI / NDA 215244 [1]; TAZPOWER RCT [9, 36]; TAZPOWER 168-wk OLE [10, 18]; MMPOWER-3 [5, 15]; ReCLAIM-2 [7, 23]). Four named objective monitoring markers are present. The eosinophilia "no defined threshold in PI" honesty is documented. No halt reasons identified. **Verdict: PASS.**
